{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T12:10:23Z","timestamp":1771243823654,"version":"3.50.1"},"reference-count":43,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2024,9,16]],"date-time":"2024-09-16T00:00:00Z","timestamp":1726444800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2024,9,16]],"date-time":"2024-09-16T00:00:00Z","timestamp":1726444800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pediatric Pulmonology"],"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Asthma imposes a crucial economic burden on health systems, especially with the incorporation of new drugs. Recently, mepolizumab has been approved to prevent exacerbations in patients with eosinophilic asthma. This study explores the economically justifiable price of mepolizumab for preventing exacerbations in children with severe asthma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods<\/jats:title>\n                    <jats:p>A model was developed using the microsimulation to estimate the quality\u2010adjusted costs and life years of two interventions: mepolizumab versus not applying standard treatment without mepolizumab. This analysis was made during a time horizon of 50 years and from a third\u2010payer perspective.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Mepolizumab was cost\u2010effective using a WTP of U$ 19,992 per QALY, but not at a WTP of U$ 4828, U$ 5128 per QALY. The economically justifiable cost for mepolizumab in Colombia is between $33 and $350 per dose, for WTP of U$ 4828, and U$ 5128 respectively. At the current price of Mepolizumab, U$ 780 per dose, only using a WTP higher than U$ 10,300 per QALY mepolizumab will be the best alternative to no mepolizumab.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our study shows that the economically justifiable cost for mepolizumab in Colombia is between $33 and $350 per dose, for WTP of 4828 and 5180 respectively. This result should encourage more studies in the region that optimize decision\u2010making processes when incorporating this drug into the health plans of each country.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ppul.27269","type":"journal-article","created":{"date-parts":[[2024,9,16]],"date-time":"2024-09-16T07:23:46Z","timestamp":1726471426000},"page":"3624-3631","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Efficient use of mepolizumab in children: An analysis of the economically justifiable price in Colombia"],"prefix":"10.1002","volume":"59","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2404-6612","authenticated-orcid":false,"given":"Jefferson Antonio","family":"Buend\u00eda","sequence":"first","affiliation":[{"name":"Departamento de Farmacolog\u00eda y Toxicolog\u00eda, Facultad de Medicina, Grupo de Investigaci\u00f3n en Farmacolog\u00eda y Toxicolog\u00eda Universidad de Antioquia Medell\u00edn Colombia"},{"name":"Division of Health Sciences, Warwick Medical School University of Warwick Coventry UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5656-4153","authenticated-orcid":false,"given":"Andres Felipe","family":"Zuluaga","sequence":"additional","affiliation":[{"name":"Departamento de Farmacolog\u00eda y Toxicolog\u00eda, Facultad de Medicina, Grupo de Investigaci\u00f3n en Farmacolog\u00eda y Toxicolog\u00eda Universidad de Antioquia Medell\u00edn Colombia"},{"name":"Laboratorio Integrado de Medicina Especializada, School of Medicine, IPS Universitaria University of Antioquia Medell\u00edn Colombia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2024,9,16]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30925-9"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.2500\/aap.2015.36.3908"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2466-12-17"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/clt2.12232"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12940-024-01060-8"},{"key":"e_1_2_8_7_1","first-page":"106","article-title":"Nucala (Mepolizumab): first IL\u20105 antagonist monoclonal antibody FDA approved for maintenance treatment of patients with severe asthma","volume":"9","author":"Fala L","year":"2016","journal-title":"Am Health Drug Benefits"},{"key":"e_1_2_8_8_1","unstructured":"AgencyEM.2015. Nucalahttps:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/nucala"},{"key":"e_1_2_8_9_1","unstructured":"Mepolizumab.Drugs and Lactation Database (LactMed(R)).2006."},{"issue":"12","key":"e_1_2_8_10_1","article-title":"Efficacy and safety of mepolizumab in the management of severe eosinophilic asthma: a systematic review","volume":"15","author":"Dighriri IM","year":"2023","journal-title":"Cureus"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1080\/02770903.2024.2303767"},{"key":"e_1_2_8_12_1","unstructured":"Prevention GSfAMa.2023. GlobalInitiative for asthma.https:\/\/ginasthma.org\/"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.3111\/13696998.2015.1025793"},{"key":"e_1_2_8_14_1","unstructured":"Institute I. The Global Use of Medicines 2024: Outlook to 2028 2024 [12\/08\/2024].https:\/\/www.iqvia.com\/insights\/the-iqvia-institute\/reports-and-publications\/reports\/the-global-use-of-medicines-2024-outlook-to-2028"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1093\/heapol\/czw096"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.318.7197.1551"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40733-016-0029-3"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.26920"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2012.06.014"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)01198-9"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00745-2022"},{"issue":"7","key":"e_1_2_8_22_1","article-title":"Anti\u2010IL\u20105 therapies for asthma","volume":"7","author":"Farne HA","year":"2022","journal-title":"Cochrane Data Syst Rev"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2022.823399"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vhri.2023.09.006"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.aller.2019.06.015"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2022.11.021"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2021.11.1351"},{"key":"e_1_2_8_28_1","unstructured":"SaludIdETe.2014. Manual metodol\u00f3gico para la elaboraci\u00f3n de evaluaciones de efectividad seguridad y validez diagn\u00f3stica de tecnolog\u00edas en salud. Bogota DC.https:\/\/www.minsalud.gov.co\/sites\/rid\/Lists\/BibliotecaDigital\/RIDE\/INEC\/IETS\/manual-metodologico-elaboracion-de-evaluaciones-de-efectividad.pdf"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiab118"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(23)00162-6"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1093\/heapol\/czab146"},{"key":"e_1_2_8_32_1","unstructured":"Departamento Nacional (DANE) DE.ArchivoNacional de Datos.2019.https:\/\/sitios.dane.gov.co\/anda-index\/"},{"key":"e_1_2_8_33_1","first-page":"31","article-title":"Perfil cl\u00ednico y costos directos de la atenci\u00f3n de asma en una red de instituciones de salud en Bogot\u00e1","volume":"31","author":"Rosselli D","year":"2020","journal-title":"Revista Colombiana de Neumolog\u00eda"},{"key":"e_1_2_8_34_1","unstructured":"Garc\u00eda Calder\u00f3nCPBM.2010. Eosin\u00f3filos en sangre y en esputo como predictores de severidad en crisis asm\u00e1ticarev. colomb. neumol.https:\/\/revistas.asoneumocito.org\/index.php\/rcneumologia\/article\/view\/679"},{"key":"e_1_2_8_35_1","unstructured":"NeffenH Fritscher C Fau \u2010 SchachtFC Schacht Fc Fau \u2010 LevyG et al. Asthma control in Latin America: the Asthma Insights and Reality in Latin America (AIRLA) survey. (1020\u20104989 (Print))."},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2016.10.028"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1080\/02770903.2020.1837158"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vhri.2022.12.007"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12931-023-02475-6"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1017\/S0266462320000033"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.1017\/S0266462321000416"},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.26033"},{"key":"e_1_2_8_43_1","doi-asserted-by":"publisher","DOI":"10.1080\/14737167.2022.2011217"},{"key":"e_1_2_8_44_1","doi-asserted-by":"publisher","DOI":"10.1080\/14737167.2021.1945445"}],"container-title":["Pediatric Pulmonology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ppul.27269","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ppul.27269","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ppul.27269","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T11:23:48Z","timestamp":1771241028000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ppul.27269"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,16]]},"references-count":43,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["10.1002\/ppul.27269"],"URL":"https:\/\/doi.org\/10.1002\/ppul.27269","archive":["Portico"],"relation":{},"ISSN":["8755-6863","1099-0496"],"issn-type":[{"value":"8755-6863","type":"print"},{"value":"1099-0496","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,16]]},"assertion":[{"value":"2024-03-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-09-07","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-09-16","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}